Mesoblast Priced, Nasdaq: MESO
Developing regenerative medicine based on adult stem cells.
Industry: Health Care
First Day Return: +1.4%
Industry: Health Care
We are a global leader in the field of regenerative medicine. We have leveraged our proprietary technology platform, which is based on specialized cells known as MLCs to establish what we believe to be the most advanced regenerative medicine product portfolio in the industry. We have what we believe to be an extensive safety profile for our product candidates, with over 1,340 patients treated. Based on outcomes in Phase 2 trials across multiple indications, we now have five MLC product candidates that are in active Phase 3 trials or are Phase 3-ready.
| IPO Data | |
|---|---|
| IPO File Date | 11/02/2015 |
| Offer Price | $8.00 |
| Price Range $8.00 - $8.00 | |
| Offer Shares (mm) | 7.5 |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 11/12/2015 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Melbourne, Australia |
| Founded | 2004 |
| Employees at IPO | 115 |
| Website www.mesoblast.com | |
Mesoblast (MESO) Performance
